BR112021017310A2 - - Google Patents

Info

Publication number
BR112021017310A2
BR112021017310A2 BR112021017310A BR112021017310A BR112021017310A2 BR 112021017310 A2 BR112021017310 A2 BR 112021017310A2 BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A BR112021017310 A BR 112021017310A BR 112021017310 A2 BR112021017310 A2 BR 112021017310A2
Authority
BR
Brazil
Application number
BR112021017310A
Other versions
BR112021017310A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021017310A2 publication Critical patent/BR112021017310A2/pt
Publication of BR112021017310A8 publication Critical patent/BR112021017310A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021017310A 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza BR112021017310A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019038662 2019-03-04
PCT/JP2020/008974 WO2020179797A1 (ja) 2019-03-04 2020-03-03 インフルエンザhaスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
BR112021017310A2 true BR112021017310A2 (pt) 2021-11-16
BR112021017310A8 BR112021017310A8 (pt) 2022-12-06

Family

ID=72337458

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017310A BR112021017310A8 (pt) 2019-03-04 2020-03-03 Método para produzir vacina fracionada de ha de influenza

Country Status (13)

Country Link
US (1) US20220152191A1 (pt)
EP (1) EP3936147A4 (pt)
JP (1) JP7545955B2 (pt)
KR (1) KR20210135261A (pt)
CN (1) CN114096273A (pt)
AU (1) AU2020233456A1 (pt)
BR (1) BR112021017310A8 (pt)
CA (1) CA3132578A1 (pt)
EA (1) EA202192398A1 (pt)
IL (1) IL285984A (pt)
MX (1) MX2021010685A (pt)
SG (1) SG11202109566XA (pt)
WO (1) WO2020179797A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374894B1 (en) * 1993-09-13 2014-09-17 Protein Sciences Corporation A method for producing influenza hemagglutinin multivalent vaccines
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2010060921A1 (en) * 2008-11-25 2010-06-03 Avir Green Hills Biotechnology Research Development Trade Ag METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES
CN102406931B (zh) * 2011-11-25 2014-02-05 成都康华生物制品有限公司 大流行流感病毒裂解疫苗
CN104302317B (zh) * 2012-05-16 2016-07-06 Kj生物科学有限公司 新型和改进的流感疫苗
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물
US20180179256A1 (en) * 2015-05-04 2018-06-28 Epivax, Inc. Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence
ES2805724T3 (es) * 2015-09-29 2021-02-15 Sumitomo Dainippon Pharma Co Ltd Compuestos de adenina conjugados y su uso como adyuvantes de vacunas
EP3603619A4 (en) * 2017-03-29 2020-12-09 Sumitomo Dainippon Pharma Co., Ltd. VACCINAL ADJUVANT FORMULATION
JP7403733B2 (ja) * 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザhaスプリットワクチンの製造方法
TW202011986A (zh) * 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
BR112021011495A8 (pt) * 2018-12-26 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Preparação incluindo adjuvante para vacina
EP3930750A4 (en) * 2019-02-28 2023-01-18 Novavax, Inc. METHODS OF PREVENTING AN ILLNESS OR DISORDER CAUSED BY RSV INFECTION

Also Published As

Publication number Publication date
EP3936147A1 (en) 2022-01-12
IL285984A (en) 2021-10-31
SG11202109566XA (en) 2021-10-28
CN114096273A (zh) 2022-02-25
WO2020179797A1 (ja) 2020-09-10
JP7545955B2 (ja) 2024-09-05
EP3936147A4 (en) 2022-09-28
US20220152191A1 (en) 2022-05-19
EA202192398A1 (ru) 2021-11-23
MX2021010685A (es) 2021-12-10
AU2020233456A1 (en) 2021-10-07
CA3132578A1 (en) 2020-09-10
KR20210135261A (ko) 2021-11-12
BR112021017310A8 (pt) 2022-12-06
JPWO2020179797A1 (pt) 2020-09-10

Similar Documents

Publication Publication Date Title
BR112019017762A2 (pt)
BR112021017339A2 (pt)
BR112021018450A2 (pt)
BR112019016141A2 (pt)
BR112021017939A2 (pt)
BR112021017738A2 (pt)
BR112021017892A2 (pt)
BR112021017782A2 (pt)
AU2020104490A5 (pt)
BR112021017637A2 (pt)
BR112021008711A2 (pt)
BR112019016142A2 (pt)
BR112019016138A2 (pt)
BR112021018168A2 (pt)
BR112021017728A2 (pt)
BR112021018452A2 (pt)
BR112021017234A2 (pt)
BR112021017355A2 (pt)
BR112021017703A2 (pt)
BR112021018102A2 (pt)
BR112021017173A2 (pt)
BR112021017083A2 (pt)
BR112021015080A2 (pt)
BR112021012348A2 (pt)
BR112021018250A2 (pt)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) ; SUMITOMO PHARMA CO., LTD. (JP)